Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00177
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
SOR-C27
|
|||||
| Structure |
|
|||||
| Sequence |
EGKLSSNDTEGGLCKEFLHPSKVDLPR
|
|||||
| Peptide Type |
Linear
|
|||||
| Receptor Name |
Transient receptor potential cation channel subfamily V member 6 (TRPV6)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
| Formula |
C127H206N36O43S
|
|||||
| Isosmiles |
[H]NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)N[H])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO[H])C(=O)N[C@@H](CO[H])C(=O)N[C@@H](CC(=O)N[H])C(=O)N[C@@H](CC(=O)O)C(=O)N[C@]([H])(C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1cn([H])cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)O)C(C)C)[C@@H](C)O[H]
|
|||||
| InChI |
InChI=1S/C127H206N36O43S/c1-62(2)44-77(142-94(170)55-137-93(169)54-139-104(183)74(33-36-97(174)175)146-123(202)102(67(11)167)161-115(194)83(52-100(180)181)152-113(192)81(50-92(132)168)151-117(196)86(57-164)157-118(197)87(58-165)156-111(190)79(46-64(5)6)148-105(184)71(26-15-18-38-128)141-95(171)56-138-103(182)70(131)32-35-96(172)173)109(188)159-89(60-207)119(198)144-72(27-16-19-39-129)106(185)145-75(34-37-98(176)177)107(186)150-80(48-68-24-13-12-14-25-68)112(191)149-78(45-63(3)4)110(189)155-85(49-69-53-135-61-140-69)125(204)163-43-23-31-91(163)121(200)158-88(59-166)116(195)143-73(28-17-20-40-130)108(187)160-101(66(9)10)122(201)153-82(51-99(178)179)114(193)154-84(47-65(7)8)124(203)162-42-22-30-90(162)120(199)147-76(126(205)206)29-21-41-136-127(133)134/h12-14,24-25,53,61-67,70-91,101-102,164-167,207H,15-23,26-52,54-60,128-131H2,1-11H3,(H2,132,168)(H,135,140)(H,137,169)(H,138,182)(H,139,183)(H,141,171)(H,142,170)(H,143,195)(H,144,198)(H,145,185)(H,146,202)(H,147,199)(H,148,184)(H,149,191)(H,150,186)(H,151,196)(H,152,192)(H,153,201)(H,154,193)(H,155,189)(H,156,190)(H,157,197)(H,158,200)(H,159,188)(H,160,187)(H,161,194)(H,172,173)(H,174,175)(H,176,177)(H,178,179)(H,180,181)(H,205,206)(H4,133,134,136)/t67-,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,101+,102+/m1/s1
|
|||||
| InChIKey |
YIOQTNCGYDKDRC-JYRIOPDISA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
2957.321
|
Polar area
|
1283.99
|
||
|
Complexity
|
2955.47602
|
xlogp Value
|
-14.8941
|
|||
|
Heavy Count
|
207
|
Rot Bonds
|
109
|
|||
|
Hbond acc
|
44
|
Hbond Donor
|
43
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
SBI1301 [Preclinical]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
10%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 0.3 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
75%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 0.6 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 1.2 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 2.4 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.3 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cell | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.4 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cell | CVCL_0035 | ||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.6 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cell | CVCL_0428 | ||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Uterine corpus sarcoma | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.7 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Uterine corpus sarcoma | MES-SA cell | CVCL_1404 | ||